Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
Jul 31, 2017  Low dose atorvastatin rapidly reversed OCA associated LDL changes Conference call scheduled for 8:30 am ET NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on...
Jul 31, 2017 Worldwide net Ocaliva® (obeticholic acid or OCA) 2Q 2017 sales of $30.4 millionAESOP Phase 2 trial in patients with PSC met its primary endpointCONTROL trial met its objective, confirming statin co-administration with OCA red...
Jul 26, 2017 NEW YORK, July 26, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its second quarter 2017 financial results prior to th...
Jun 22, 2017 NEW YORK, June 22, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Ocaliva® (obeticholic acid) has been granted the 2017 Pr...
Jun 12, 2017 Post-hoc analysis showed that patients with both type 2 diabetes and NASH had high rates of advanced fibrosisOCA-treated patients achieved statistically significant improvements in all histologic measures, including fibrosisNew findings presented at the American Diabetes Association's Scientific Ses...
May 25, 2017 NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Health Canada has granted a conditional approval for Ocaliva (obeticholic acid) for th...
May 19, 2017 NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has received a 2017 Industry Innovation Award from the ...
May 17, 2017 NEW YORK, May 17, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:...
May 4, 2017 Worldwide net Ocaliva® (obeticholic acid or OCA) 1Q 2017 sales of $20.6 millionCompleted enrollment of Phase 3 REGENERATE trial interim analysis cohort: data expected in 1H 2019 Conference call scheduled for 8:30 a....
Apr 27, 2017 NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its first quarter 2017 financial results prior to the NASDAQ market open o...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase